In conclusion, our results demonstrate that rSmeg-hMIF-hIL-7 therapy elicits a strong anticancer immune response in mice, mainly via reduction of tumor-derived MIF level, neutralization of MIF or the recruitment of activated lymphocytes capable of downregulating the MIF downstream signaling pathway, indicating the potential use of rSmeg-hMIF-hIL-7 as adjunctive immunotherapy capable of enhancing the efficacy of immunotherapy. The gene discussed is MIF; the disease is neoplasm.